These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 7083201)
21. Breast cancer aromatase expression evaluated by the novel antibody 677: correlations to intra-tumor estrogen levels and hormone receptor status. Geisler J; Suzuki T; Helle H; Miki Y; Nagasaki S; Duong NK; Ekse D; Aas T; Evans DB; Lønning PE; Sasano H J Steroid Biochem Mol Biol; 2010 Feb; 118(4-5):237-41. PubMed ID: 19883757 [TBL] [Abstract][Full Text] [Related]
22. Preliminary studies of aromatase in human neoplastic endometrium. Tseng L; Mazella J; Funt MI; Mann WJ; Stone ML Obstet Gynecol; 1984 Feb; 63(2):150-4. PubMed ID: 6694807 [TBL] [Abstract][Full Text] [Related]
23. Correlation of aromatase activity and steroid receptors in human ovarian carcinoma. Kühnel R; Delemarre JF; Rao BR; Stolk JG Anticancer Res; 1986; 6(5):889-92. PubMed ID: 3026234 [TBL] [Abstract][Full Text] [Related]
24. HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Dowsett M; Harper-Wynne C; Boeddinghaus I; Salter J; Hills M; Dixon M; Ebbs S; Gui G; Sacks N; Smith I Cancer Res; 2001 Dec; 61(23):8452-8. PubMed ID: 11731427 [TBL] [Abstract][Full Text] [Related]
25. The role of aromatase and 17-beta-hydroxysteroid dehydrogenase type 1 mRNA expression in predicting the clinical outcome of human breast cancer. Salhab M; Reed MJ; Al Sarakbi W; Jiang WG; Mokbel K Breast Cancer Res Treat; 2006 Sep; 99(2):155-62. PubMed ID: 16541304 [TBL] [Abstract][Full Text] [Related]
26. Aromatase inhibitors: rationale for use following antiestrogen therapy. Yue W; Santen RJ Semin Oncol; 1996 Aug; 23(4 Suppl 9):21-7. PubMed ID: 8824461 [TBL] [Abstract][Full Text] [Related]
27. Aromatase localization in human breast cancer tissues: possible interactions between intratumoral stromal and parenchymal cells. Miki Y; Suzuki T; Tazawa C; Yamaguchi Y; Kitada K; Honma S; Moriya T; Hirakawa H; Evans DB; Hayashi S; Ohuchi N; Sasano H Cancer Res; 2007 Apr; 67(8):3945-54. PubMed ID: 17440110 [TBL] [Abstract][Full Text] [Related]
28. Steroid hormone profiles in women treated with aminoglutethimide for metastatic carcinoma of the breast. Samojlik E; Santen RJ; Kirschner MA; Ertel NH Cancer Res; 1982 Aug; 42(8 Suppl):3349s-3352s. PubMed ID: 7083199 [TBL] [Abstract][Full Text] [Related]
29. Estrogen production via the aromatase enzyme in breast carcinoma: which cell type is responsible? Santen RJ; Santner SJ; Pauley RJ; Tait L; Kaseta J; Demers LM; Hamilton C; Yue W; Wang JP J Steroid Biochem Mol Biol; 1997 Apr; 61(3-6):267-71. PubMed ID: 9365200 [TBL] [Abstract][Full Text] [Related]
30. Anastrozole ('Arimidex') blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer. Miller WR; Stuart M; Sahmoud T; Dixon JM Br J Cancer; 2002 Oct; 87(9):950-5. PubMed ID: 12434282 [TBL] [Abstract][Full Text] [Related]
31. A correlation between estrogen sulfotransferase levels and estrogen receptor status in human primary breast carcinoma. Adams JB; Pewnim T; Chandra DP; Archibald L; Foo MS Cancer Res; 1979 Dec; 39(12):5124-6. PubMed ID: 498139 [TBL] [Abstract][Full Text] [Related]
32. Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program. Lane HA; Lebwohl D Semin Oncol; 2006 Apr; 33(2 Suppl 7):S18-25. PubMed ID: 16730273 [TBL] [Abstract][Full Text] [Related]
33. Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third-generation aromatase inhibitor vorozole. de Jong PC; van de Ven J; Nortier HW; Maitimu-Smeele I; Donker TH; Thijssen JH; Slee PH; Blankenstein RA Cancer Res; 1997 Jun; 57(11):2109-11. PubMed ID: 9187104 [TBL] [Abstract][Full Text] [Related]
34. Increases in serum estrogen levels during major illness are caused by increased peripheral aromatization. Spratt DI; Morton JR; Kramer RS; Mayo SW; Longcope C; Vary CP Am J Physiol Endocrinol Metab; 2006 Sep; 291(3):E631-8. PubMed ID: 16670151 [TBL] [Abstract][Full Text] [Related]
35. Intratumoral aromatase as a prognostic factor in human breast carcinoma. Silva MC; Rowlands MG; Dowsett M; Gusterson B; McKinna JA; Fryatt I; Coombes RC Cancer Res; 1989 May; 49(10):2588-91. PubMed ID: 2713843 [TBL] [Abstract][Full Text] [Related]
36. Local biosynthesis of estrogen in human endometrial carcinoma through tumor-stromal cell interactions. Takahashi-Shiga N; Utsunomiya H; Miki Y; Nagase S; Kobayashi R; Matsumoto M; Niikura H; Ito K; Yaegashi N Clin Cancer Res; 2009 Oct; 15(19):6028-34. PubMed ID: 19789322 [TBL] [Abstract][Full Text] [Related]
37. Induction of aromatase (CYP19) expression in breast cancer cells through a nongenomic action of estrogen receptor alpha. Kinoshita Y; Chen S Cancer Res; 2003 Jul; 63(13):3546-55. PubMed ID: 12839940 [TBL] [Abstract][Full Text] [Related]
38. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. Cui X; Schiff R; Arpino G; Osborne CK; Lee AV J Clin Oncol; 2005 Oct; 23(30):7721-35. PubMed ID: 16234531 [TBL] [Abstract][Full Text] [Related]
39. Aromatase in the central nervous system. Naftolin F; MacLusky NJ Cancer Res; 1982 Aug; 42(8 Suppl):3274s-3276s. PubMed ID: 7083185 [TBL] [Abstract][Full Text] [Related]
40. Tumor-stromal interaction through the estrogen-signaling pathway in human breast cancer. Yamaguchi Y; Takei H; Suemasu K; Kobayashi Y; Kurosumi M; Harada N; Hayashi S Cancer Res; 2005 Jun; 65(11):4653-62. PubMed ID: 15930283 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]